Cabozantinib Cutaneous Toxicity—Comprehensive Review
Background: In the context of modern cancer therapy, the management of adverse effects of systemic therapies can lead to the avoidance of underdosing and withdrawal and increases in the quality of the therapeutic act and the quality of life. This review offers an overview of the skin-related toxicit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/15/1/72 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588149507751936 |
|---|---|
| author | Cristina Violeta Tutunaru Dragos Ovidiu Alexandru Sanda Amelia Dracea Loredana Ungureanu Liliana Gabriela Popa Cristina Beiu |
| author_facet | Cristina Violeta Tutunaru Dragos Ovidiu Alexandru Sanda Amelia Dracea Loredana Ungureanu Liliana Gabriela Popa Cristina Beiu |
| author_sort | Cristina Violeta Tutunaru |
| collection | DOAJ |
| description | Background: In the context of modern cancer therapy, the management of adverse effects of systemic therapies can lead to the avoidance of underdosing and withdrawal and increases in the quality of the therapeutic act and the quality of life. This review offers an overview of the skin-related toxicities associated with Cabozantinib, a multikinase inhibitor (MKI) that is approved for treating advanced kidney cancer, hepatocellular carcinoma, and medullary thyroid cancer. It covers the most common dermatological side effects, such as palmar–plantar erythrodysesthesia, stomatitis, hair alterations, xerosis, scrotal erythema, and subungual splinter hemorrhages. Additionally, this review includes suggested preventive strategies and management approaches based on the severity of these adverse effects. |
| format | Article |
| id | doaj-art-9cc7b48fc5d54ee2b4d70ad07f5de804 |
| institution | Kabale University |
| issn | 2075-1729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-9cc7b48fc5d54ee2b4d70ad07f5de8042025-01-24T13:38:40ZengMDPI AGLife2075-17292025-01-011517210.3390/life15010072Cabozantinib Cutaneous Toxicity—Comprehensive ReviewCristina Violeta Tutunaru0Dragos Ovidiu Alexandru1Sanda Amelia Dracea2Loredana Ungureanu3Liliana Gabriela Popa4Cristina Beiu5Department of Dermatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaDepartment of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaDepartment of Biophysics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, RomaniaDepartment of Dermatology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, RomaniaDepartment of Oncologic Dermatology, “Elias” Emergency University Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, RomaniaDepartment of Oncologic Dermatology, “Elias” Emergency University Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, RomaniaBackground: In the context of modern cancer therapy, the management of adverse effects of systemic therapies can lead to the avoidance of underdosing and withdrawal and increases in the quality of the therapeutic act and the quality of life. This review offers an overview of the skin-related toxicities associated with Cabozantinib, a multikinase inhibitor (MKI) that is approved for treating advanced kidney cancer, hepatocellular carcinoma, and medullary thyroid cancer. It covers the most common dermatological side effects, such as palmar–plantar erythrodysesthesia, stomatitis, hair alterations, xerosis, scrotal erythema, and subungual splinter hemorrhages. Additionally, this review includes suggested preventive strategies and management approaches based on the severity of these adverse effects.https://www.mdpi.com/2075-1729/15/1/72cabozantinibcutaneous toxicityrenal cell carcinomamedicationadverse effects |
| spellingShingle | Cristina Violeta Tutunaru Dragos Ovidiu Alexandru Sanda Amelia Dracea Loredana Ungureanu Liliana Gabriela Popa Cristina Beiu Cabozantinib Cutaneous Toxicity—Comprehensive Review Life cabozantinib cutaneous toxicity renal cell carcinoma medication adverse effects |
| title | Cabozantinib Cutaneous Toxicity—Comprehensive Review |
| title_full | Cabozantinib Cutaneous Toxicity—Comprehensive Review |
| title_fullStr | Cabozantinib Cutaneous Toxicity—Comprehensive Review |
| title_full_unstemmed | Cabozantinib Cutaneous Toxicity—Comprehensive Review |
| title_short | Cabozantinib Cutaneous Toxicity—Comprehensive Review |
| title_sort | cabozantinib cutaneous toxicity comprehensive review |
| topic | cabozantinib cutaneous toxicity renal cell carcinoma medication adverse effects |
| url | https://www.mdpi.com/2075-1729/15/1/72 |
| work_keys_str_mv | AT cristinavioletatutunaru cabozantinibcutaneoustoxicitycomprehensivereview AT dragosovidiualexandru cabozantinibcutaneoustoxicitycomprehensivereview AT sandaameliadracea cabozantinibcutaneoustoxicitycomprehensivereview AT loredanaungureanu cabozantinibcutaneoustoxicitycomprehensivereview AT lilianagabrielapopa cabozantinibcutaneoustoxicitycomprehensivereview AT cristinabeiu cabozantinibcutaneoustoxicitycomprehensivereview |